Life sciences is a highly regulated industry which has seen
exponential growth over the last several years of disruption. When
a business has the potential to affect health (whether human or
veterinary), there is a host of approvals, regulations, and
compliance that must be contended with. And now with more eyes than
ever focused on the sector, regulatory oversight remains a top
priority for companies that operate within it.
Ideally, regulatory challenges will be hurdled smoothly; however,
in times when this does not work out as hoped, companies must turn
to the courts and administrative law to resolve issues. Two recent
decisions of the Federal Court of Appeal show that, after the
Supreme Court's 2019 decision
in Vavilov1, the courts may be more
willing to intervene.
